CL2023001293A1 - Procedimiento de fabricación para productos biológicos mediante integración de procedimientos principio activo - producto terminado - Google Patents

Procedimiento de fabricación para productos biológicos mediante integración de procedimientos principio activo - producto terminado

Info

Publication number
CL2023001293A1
CL2023001293A1 CL2023001293A CL2023001293A CL2023001293A1 CL 2023001293 A1 CL2023001293 A1 CL 2023001293A1 CL 2023001293 A CL2023001293 A CL 2023001293A CL 2023001293 A CL2023001293 A CL 2023001293A CL 2023001293 A1 CL2023001293 A1 CL 2023001293A1
Authority
CL
Chile
Prior art keywords
active ingredient
finished product
integration
biological products
manufacturing procedure
Prior art date
Application number
CL2023001293A
Other languages
English (en)
Inventor
R Ambhaikar Malhar
CHAI Vincent
Clark Philip
Guhan Subramanian
Chakradhar PADALA Sai
Rathore Nitin
SAREMI Zane
Sharma Ashish
Shoemaker Kenneth
Thangaraj Balakumar
E Thorup John
J Tillotson Benjamin
WONG Hann-Chung
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of CL2023001293A1 publication Critical patent/CL2023001293A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
    • B01D61/14—Ultrafiltration; Microfiltration
    • B01D61/145—Ultrafiltration
    • B01D61/146—Ultrafiltration comprising multiple ultrafiltration steps
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D2315/00—Details relating to the membrane module operation
    • B01D2315/16—Diafiltration
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D2317/00—Membrane module arrangements within a plant or an apparatus
    • B01D2317/02—Elements in series
    • B01D2317/022—Reject series
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D63/00—Apparatus in general for separation processes using semi-permeable membranes
    • B01D63/02—Hollow fibre modules
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D71/00—Semi-permeable membranes for separation processes or apparatus characterised by the material; Manufacturing processes specially adapted therefor
    • B01D71/06—Organic material
    • B01D71/30—Polyalkenyl halides
    • B01D71/32—Polyalkenyl halides containing fluorine atoms
    • B01D71/34—Polyvinylidene fluoride
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific

Abstract

Procedimiento de fabricación de productos biológicos que conecta los procedimientos de principio activo y producto terminado en un procedimiento continuo, integrado.
CL2023001293A 2019-01-28 2023-05-04 Procedimiento de fabricación para productos biológicos mediante integración de procedimientos principio activo - producto terminado CL2023001293A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962797445P 2019-01-28 2019-01-28

Publications (1)

Publication Number Publication Date
CL2023001293A1 true CL2023001293A1 (es) 2023-10-06

Family

ID=69740575

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2021001958A CL2021001958A1 (es) 2019-01-28 2021-07-26 Procedimiento de fabricación continuo para la fabricación de productos biológicos mediante integración de procedimientos de principio activo y producto terminado.
CL2023001293A CL2023001293A1 (es) 2019-01-28 2023-05-04 Procedimiento de fabricación para productos biológicos mediante integración de procedimientos principio activo - producto terminado

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CL2021001958A CL2021001958A1 (es) 2019-01-28 2021-07-26 Procedimiento de fabricación continuo para la fabricación de productos biológicos mediante integración de procedimientos de principio activo y producto terminado.

Country Status (16)

Country Link
US (1) US20220119526A1 (es)
EP (1) EP3917494A1 (es)
JP (1) JP2022523025A (es)
KR (1) KR20210120032A (es)
CN (1) CN113382716A (es)
AR (1) AR117896A1 (es)
AU (1) AU2020216108A1 (es)
BR (1) BR112021014634A2 (es)
CA (1) CA3127258A1 (es)
CL (2) CL2021001958A1 (es)
EA (1) EA202192108A1 (es)
IL (1) IL284782A (es)
MX (1) MX2021008985A (es)
SG (1) SG11202107714VA (es)
TW (1) TW202043253A (es)
WO (1) WO2020159838A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220396599A1 (en) * 2019-11-13 2022-12-15 Amgen Inc. Method for Reduced Aggregate Formation in Downstream Processing of Bispecific Antigen-Binding Molecules
TW202140511A (zh) 2020-01-15 2021-11-01 瑞士商赫孚孟拉羅股份公司 減少來自重組蛋白生產過程中的雜質之方法
WO2024054414A1 (en) 2022-09-06 2024-03-14 Amgen Inc. Lean perfusion cell culture methods
WO2024059235A2 (en) 2022-09-16 2024-03-21 Amgen Inc. A method for harvesting products from perfusion cultures

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6319494B1 (en) 1990-12-14 2001-11-20 Cell Genesys, Inc. Chimeric chains for receptor-associated signal transduction pathways
IL104570A0 (en) 1992-03-18 1993-05-13 Yeda Res & Dev Chimeric genes and cells transformed therewith
AU761587B2 (en) 1998-04-21 2003-06-05 Amgen Research (Munich) Gmbh CD19xCD3 specific polypeptides and uses thereof
DE602004030811D1 (de) 2003-10-16 2011-02-10 Micromet Ag Multispezifische deimmunisierte cd3-bindende moleküle
US20060051347A1 (en) * 2004-09-09 2006-03-09 Winter Charles M Process for concentration of antibodies and therapeutic products thereof
ES2695047T3 (es) 2007-04-03 2018-12-28 Amgen Research (Munich) Gmbh Dominio de unión específico entre especies
ES2680151T3 (es) 2012-03-01 2018-09-04 Amgen Research (Munich) Gmbh Moléculas de unión de polipéptidos de larga duración
US20140308285A1 (en) 2013-03-15 2014-10-16 Amgen Inc. Heterodimeric bispecific antibodies
LT2970449T (lt) 2013-03-15 2019-11-25 Amgen Res Munich Gmbh Viengrandės surišančios molekulės, apimančios n galo abp
US20140302037A1 (en) 2013-03-15 2014-10-09 Amgen Inc. BISPECIFIC-Fc MOLECULES
US11634502B2 (en) 2013-03-15 2023-04-25 Amgen Inc. Heterodimeric bispecific antibodies
EP3049440B1 (en) 2013-09-25 2020-03-25 Amgen Inc. V-c-fc-v-c antibody
WO2016005903A2 (en) * 2014-07-08 2016-01-14 Theramyt Novobiologics Private Limited A process for obtaining exendin-4
KR20180037056A (ko) * 2015-09-22 2018-04-10 화이자 인코포레이티드 치료학적 단백질 제형의 제조 방법 및 이러한 방법에 의해 생산된 항체 제형
KR20180074775A (ko) * 2015-10-26 2018-07-03 론자 리미티드 생물약제의 생산을 위한 제조 설비
EA039859B1 (ru) * 2016-02-03 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
EP3724229A1 (en) 2017-12-11 2020-10-21 Amgen Inc. Continuous manufacturing process for bispecific antibody products

Also Published As

Publication number Publication date
CL2021001958A1 (es) 2022-01-28
BR112021014634A2 (pt) 2021-10-26
WO2020159838A1 (en) 2020-08-06
TW202043253A (zh) 2020-12-01
MX2021008985A (es) 2021-09-08
IL284782A (en) 2021-08-31
EP3917494A1 (en) 2021-12-08
CN113382716A (zh) 2021-09-10
JP2022523025A (ja) 2022-04-21
AU2020216108A1 (en) 2021-08-12
AR117896A1 (es) 2021-09-01
CA3127258A1 (en) 2020-08-06
EA202192108A1 (ru) 2021-10-21
SG11202107714VA (en) 2021-08-30
US20220119526A1 (en) 2022-04-21
KR20210120032A (ko) 2021-10-06

Similar Documents

Publication Publication Date Title
CL2023001293A1 (es) Procedimiento de fabricación para productos biológicos mediante integración de procedimientos principio activo - producto terminado
USD850071S1 (en) Shoe
USD833024S1 (en) Belt bandage
CL2021000415A1 (es) Vesículas derivadas de lactobacillus paracasei y uso de las mismas
USD866621S1 (en) Laser cutting machine
USD812759S1 (en) Optical coherence tomography apparatus for ophthalmology
MX2016009720A (es) Sistema dispensador para productos de papel sanitario.
AR033127A1 (es) Producto alimenticio lacteo con caracteristicas semejantes al queso tradicional
USD831979S1 (en) Rolled tissue product
CL2018001775A1 (es) Unidades de administración de agroquímicos de liberación controlada, su fabricación y uso
PH12016501841A1 (en) Immunosuppressant formulation
UY36761A (es) Formulación oral sólida que contiene irinotecán y método 20 de preparación de la misma
USD772401S1 (en) Absorbent article
USD772402S1 (en) Absorbent article
CO2019014354A2 (es) Aparato y metodo para la fabricacion de charolas para empaque con diferentes estructuras y producto obtenido
USD719791S1 (en) Cookie cutter
USD804655S1 (en) Catamenial tampon
IT201700057784A1 (it) Metodo per la preparazione e l'erogazione di una dose di un mezzo di contrasto gassoso per l'esecuzione di angiografie, e dispositivo che attua tale metodo
CO2018014217A2 (es) Composiciones farmacéuticas que comprenden safinamida
NI202000044S (es) Bandejas de fabricación
USD772403S1 (en) Absorbent article
CA165226S (en) Angled pump
CL2018003338A1 (es) Formulaciones inyectables fisiológicamente balanceadas de fosnetupitant.
AR103141A1 (es) Proceso para tratamiento de lana y productos
AR115642A1 (es) Preparación alimenticia